Due to the unavailability of the raw material global bovine insulin API, Wockhardt has been forced to discontinue the Hypurin® Bovine Insulin range.

The company says that residual bovine insulin stocks will be carefully managed to ensure product remains available for patients for as long as possible. However, all patients using Hypurin® Bovine Insulin will need to have their prescription changed.

The company emphasises that the discontinuation of Hypurin® BOVINE Insulin does not affect the supply of Hypurin® PORCINE Insulin.

You can find monthly updates on depletion dates on the company website here.

For medical information call +44 1978 669260 or for supply enquiries call +44 1978 669359


E-cigarette key weapon in NHS arsenal, say MPs

E-cigarettes should not be treated in the same way as conventional cigarettes, say MPs.

Aggressive lowering of systolic BP reduces dementia risk

Reductions in the risk of mild cognitive impairment (MCI), and the combination of MCI and dementia, have been shown for...

This website is for healthcare professionals only. By clicking "Accept" to hide this message or by clicking into any content on this website, you confirm you are a healthcare professional, consent to accepting cookies in accordance with our Cookie Policy and agree to Independent Pharmacist’s Terms of Use and Privacy Policy.